FOLD (Amicus Therapeutics Inc.) stock is in for a key growth catalyst

Amicus Therapeutics Inc. (NASDAQ: FOLD) closed the day trading at $11.14 down -4.87% from the previous closing price of $11.71. In other words, the price has decreased by -$0.57 from its previous closing price. On the day, 2019674 shares were traded. FOLD stock price reached its highest trading level at $11.68 during the session, while it also had its lowest trading level at $11.09.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.



For a better understanding of FOLD, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.70 and its Current Ratio is at 2.90. In the meantime, Its Debt-to-Equity ratio is 3.83 whereas as Long-Term Debt/Eq ratio is at 3.83.

Upgrades & Downgrades

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 15 when Crowley John F sold 6,044 shares for $11.18 per share. The transaction valued at 67,577 led to the insider holds 962,361 shares of the business.

Campbell Bradley L sold 11,700 shares of FOLD for $138,093 on May 01. The President & CEO now owns 823,454 shares after completing the transaction at $11.80 per share. On May 01, another insider, Crowley John F, who serves as the Executive Chairman of the company, sold 6,044 shares for $11.80 each. As a result, the insider received 71,335 and left with 968,405 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FOLD now has a Market Capitalization of 3.20B and an Enterprise Value of 3.36B. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.10 while its Price-to-Book (P/B) ratio in mrq is 31.83. Its current Enterprise Value per Revenue stands at 9.97 whereas that against EBITDA is -20.01.

Stock Price History:

Over the past 52 weeks, FOLD has reached a high of $13.84, while it has fallen to a 52-week low of $7.34. The 50-Day Moving Average of the stock is 11.45, while the 200-Day Moving Average is calculated to be 11.65.

Shares Statistics:

Over the past 3-months, FOLD traded about 2.49M shares per day on average, while over the past 10 days, FOLD traded about 3.51M shares per day. A total of 291.34M shares are outstanding, with a floating share count of 251.96M. Insiders hold about 0.80% of the company’s shares, while institutions hold 105.77% stake in the company. Shares short for FOLD as of Apr 27, 2023 were 21.53M with a Short Ratio of 21.30M, compared to 19.98M on Mar 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 7.60% and a Short% of Float of 7.64%.

Earnings Estimates

Current recommendations for the stock of the company come from 9 analysts. On average, analysts expect EPS of -$0.13 for the current quarter, with a high estimate of -$0.09 and a low estimate of -$0.18, while EPS last year was -$0.21. The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.06 and low estimates of -$0.14.

Analysts are recommending an EPS of between -$0.33 and -$0.6 for the fiscal current year, implying an average EPS of -$0.48. EPS for the following year is $0.14, with 10 analysts recommending between $0.65 and -$0.14.

Revenue Estimates

10 analysts predict $89.87M in revenue for the current quarter. It ranges from a high estimate of $93.34M to a low estimate of $87M. As of the current estimate, Amicus Therapeutics Inc.’s year-ago sales were $80.73M, an estimated increase of 11.30% from the year-ago figure. For the next quarter, 10 analysts are estimating revenue of $99.49M, an increase of 18.10% over than the figure of $11.30% in the same quarter last year. There is a high estimate of $106.56M for the next quarter, whereas the lowest estimate is $89.7M.

A total of 12 analysts have provided revenue estimates for FOLD’s current fiscal year. The highest revenue estimate was $418.57M, while the lowest revenue estimate was $357.9M, resulting in an average revenue estimate of $392.82M. In the same quarter a year ago, actual revenue was $329.23M, up 19.30% from the average estimate. Based on 12 analysts’ estimates, the company’s revenue will be $547.9M in the next fiscal year. The high estimate is $671M and the low estimate is $423.5M. The average revenue growth estimate for next year is up 39.50% from the average revenue estimate for this year.